Compare ACON & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACON | XRTX |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4M | 4.4M |
| IPO Year | 2022 | N/A |
| Metric | ACON | XRTX |
|---|---|---|
| Price | $5.82 | $0.61 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $23.00 | N/A |
| AVG Volume (30 Days) | ★ 66.3K | 50.8K |
| Earning Date | 11-12-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $67,483.00 | N/A |
| Revenue This Year | $145.39 | N/A |
| Revenue Next Year | $145.45 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 36.91 | N/A |
| 52 Week Low | $5.55 | $0.52 |
| 52 Week High | $3,499.49 | $1.79 |
| Indicator | ACON | XRTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.43 | 43.19 |
| Support Level | $5.75 | $0.58 |
| Resistance Level | $6.89 | $0.62 |
| Average True Range (ATR) | 0.62 | 0.03 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 7.14 | 12.35 |
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.